Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Conference call May 9th Folks!!
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.
The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Virios Therapeutics Conference Call" using the access code: 739495.
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system. The Company’s lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dosage combination of famciclovir and celecoxib) has been granted fast track designation by the FDA.
For more information, please visit www.virios.com.
Exactly😎
The BASHERS are going to hate the move that DRYWORLD BRANDS is about to bring🤣😎💰
How many months have you been on the BID while spewing nonsense? DRYWORLD BRANDS LONG💰
You’ll NEVER KNOW what I do with my portfolio, but at least I have one.
Yeah right🤣 They gave the finger all the way to .735 😆 Fools for NOT SELLING, but blame the company Bwahahahahah!!
Yeah man, and VIRI is definitely a buy and hold in my book.👍
I’ll be right here waiting no matter how long it takes.😎
I truly believe it’s going to be worth the wait bud😎💰
Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat.
That’s a good sign😎 Don’t buy at the close, or these assholes will say your just PAINTING IT🤣
Yep😌
They’re looking to vote on a R/S folks!! I knew this was coming!!
https://www.otcmarkets.com/filing/html?id=17458461&guid=q7Q-knD4BCczB3h
Another Form-4. There’s some weird shit going on! Why would this guy sell $39 worth of stock😳🤣
https://www.sec.gov/Archives/edgar/data/1407973/000156218024003434/xslF345X05/primarydocument.xml
Definitely bud. SONX.
Lol🤣 I’m always on the clock bud😎
My Magic 8 Ball says hell yeah!😎💰
They’re not getting this to a $4 BID without a R/S unfortunately.
4-6 weeks once submitted.
No doubt about that😎 DRYWORLD LONG💰
I’m still here bud👍 Been here for 4 years now😎
I wouldn’t count on NASDAQ either, but OTCQX still isn’t a bad place to be.
No telling bud, but the company needs to address the shareholders now!🤷♂️
Yes it does! Now we know why the CFO and all these directors keep leaving! I’m afraid SONX will be seeing a new 52 week low soon!
Keep bringing the social media posts😎 I have a feeling we’re close to GREATNESS💰
As reported in US News and World Reporthttps://t.co/0q8eMme3FB pic.twitter.com/uKVD3yB8Op
— Virios Therapeutics (@ViriosBiotech) April 11, 2024
Maybe they’re getting bought out😎
I’m well aware. Thanks.
Insiders have acquired several hundred thousand shares since November 2023, while only dumping a few thousand. Very telling. SONX RUN COMING💰
Take a look at the 13G’s filed on Valentine’s Day. Very telling. This is setting up for a huge run.
https://www.otcmarkets.com/stock/SONX/disclosure
They didn’t want toxic notes. They made $43 Million last year, and are projected to make at least $30 Million this year. Best of luck to you as well.